On Monday 8 June, the European Medicines Agency (EMA) announced that it had received a conditional application for approval to use Remesivir as a treatment for Covid-19.
The drug, which was developed by Gilead Sciences and initially designed to combat the Ebola virus, does not yet have marketing approval in Europe, even though it is already being used in Europe for clinical trials and for compassionate use (for patients with no other medical options available).
The EMA has stated that it has...